期刊文献+

拉克替醇治疗便秘的多中心随机单盲平行对照试验 被引量:6

A Multicenter,Randomized,Single-blinded,Parallel-controlled Trial on Lactitol in Treatment of Constipation
下载PDF
导出
摘要 拉克替醇在国外已作为治疗肝性脑病和便秘的药物上市,但在国内尚未被推荐用于治疗便秘。目的:评价拉克替醇治疗便秘的疗效和安全性。方法:从4个临床医学中心随机纳入符合便秘诊断标准和研究要求的患者.随机分为试验组和对照组。试验组起始剂量(第1d)为拉克替醇20g,维持剂量(第2.7d)为每天10g:对照组起始剂量(第1d)为乳果糖20g,维持剂量(第2~7d)为每天10g。每天早餐时一次服完,疗程7d。排便次数≥3次,d或粪便性状呈Bristol6、7型时,可减半用量。结果:纳入疗效分析的病例数为129例,试验组63例.对照组66例。试验组与对照组治疗前一般情况无明显差异,便秘病情严重程度分布均衡。试验组和对照组用药3d后有效排便次数转正常率分别为77.8%和77.3%,粪便性状转正常率分别为62.2%和56.5%,用药7d后分别为95.2%和95.5%、60.4%和60.8%,两组间差异均无统计学意义。两组不良反应发生率分别为4.8%和4.5%,差异亦无统计学意义。结论:拉克替醇治疗便秘有效、安全.可在临床上推广使用。 Lactitol is used for treatment of hepatic encephalopathy and constipation in abroad, however, it has not been recommended for treatment of constipation in domestic guidelines. Aims: To assess the efficacy and safety of lactitol in treatment of constipation. Methods: Patients fulfilling the diagnostic criteria of constipation and inclusion and exclusion criteria of the study were randomly enrolled from 4 clinical medical centers and allocated into treatment group and control group. Patients in treatment group received lactitol 20 g on day 1 and 10 g/d on day 2-7, while patients in control group received lactulose 20 g on day 1 and 10 g/d on day 2-7. Drugs were taken orally with breakfast once a day for 7 days. If the frequency of defecation was beyond 3 times per day or the stool form presented as Bristol type 6 or 7, half dosage was recommended. Results: A total of 129 patients were included for efficacy analysis, 63 in treatment group and 66 in control group. General conditions and severity of constipation were comparable between these two groups before treatment. Normalization rates of defecation times were 77.8% and 77.3% for 3-day treatment, and 95.2% and 95.5% for 7-day treatment in treatment group and control group, respectively. Normalization rates of stool form were 62.2% and 56.5% for 3-day treatment, and 60.4% and 60.8% for 7-day treatment in these two groups, respectively. Differences between these two groups were not statistically significant. Rates of adverse effects in these two groups were similar (4.8% vs. 4.5%). Conclusions: Lactitol is safe and effective in treatment of constipation and may be used clinically.
出处 《胃肠病学》 2012年第3期168-172,共5页 Chinese Journal of Gastroenterology
关键词 拉克替醇 乳果糖 便秘 治疗 临床试验 Lactitol Lactulose Constipation Therapy Clinical Trials
  • 相关文献

参考文献10

  • 1Morgan MY,Hawley KE,Stambuk D. Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy.A double-blind,randomised,cross-over study[J].Journal of Hepatology,1987,(02):236-244.
  • 2Blanc P,Daures JP,Rouillon JM. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy:results of a meta-analysis[J].Hepatology,1992,(02):222-228.
  • 3Walder M,Buclin T,Biollaz J. Dose-response curve and preliminary clinical study of a laxative,lactitol (Article in French)[J].Schweizerische Medizinische Wochenschrift,1988,(50):1925-1927.
  • 4Delas N,Gislon J,Glikmanas M. Lactitol in the treatment of constipation in the adult.Open,noncomparative study of its efficacy and its clinical and biological tolerance (Article in French)[J].Ann Gastroenterol Hepatol (Paris),1991,(05):231-233.
  • 5Pitzalis G,Deganello F,Mariani P. Lactitol in chronic idiopathic constipation in children (Article in Italian)[J].Pediatria Medica E Chirurgica,1995,(03):223-226.
  • 6Copé R,Debou JM,Cohen S. Study of early postoperative lactitol versus paraffin following anal surgery in 110 adult patients (Article in French)[J].Annales de Chirurgie,1996,(07):570-576.
  • 7Longstreth GF,Thompson WG,Chey WD. Functional bowel disorders[J].Gastroenterology,2006,(05):1480-1491.doi:10.1053/j.gastro.2005.11.061.
  • 8方秀才,柯美云,罗金燕,杨新庆,刘宝华.中国慢性便秘的诊治指南(2007,扬州)[J].中华消化杂志,2007,27(9):619-622. 被引量:305
  • 9郭晓峰,柯美云,王智凤,方秀才,吴冰,涂银萍.慢性便秘的动力障碍分型及其对治疗的指导意义[J].胃肠病学,2003,8(4):200-203. 被引量:68
  • 10Zhao YF,Ma XQ,Wang R. Epidemiology of functional constipation and comparison with constipationpredominant irritable bowel syndrome:the Systematic Investigation of Gastrointestinal Diseases in China (SILC)[J].Alimentary Pharmacology and Therapeutics,2011,(08):1020-1029.

二级参考文献17

共引文献362

同被引文献36

引证文献6

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部